Article Details
Retrieved on: 2025-01-02 17:15:54
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Capricor Therapeutics' submission of a biologics license application for Deramiocel, targeting Duchenne muscular dystrophy cardiomyopathy. Supported by trial data, the therapy aligns with FDA's regenerative medicine initiatives, emphasizing potential long-term benefits.
Article found on: www.cgtlive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here